I-01 META-EPIDEMIOLOGY: BUILDING THE BRIDGE FROM RESEARCH EVIDENCE TO CLINICAL PRACTICE  by Zhang, W.
Osteoarthritis and Cartilage 18, Supplement 2 (2010) S1–S8
Abstracts from Invited Speakers
I-01
META-EPIDEMIOLOGY: BUILDING THE BRIDGE FROM RESEARCH
EVIDENCE TO CLINICAL PRACTICE
W. Zhang
Nottingham Univ., Nottingham, United Kingdom
Meta-epidemiology evolves from epidemiology and meta-analysis. It is a
subject which attempts to describe distribution of research evidence for
a speciﬁc question, examine heterogeneity and associated risk factors,
identify and control bias across studies and summarise research evidence
as appropriate. Unlike classic epidemiology, the observational subjects of
meta-epidemiology are papers not patients. It is therefore an observational
study in research evidence with a unique statistical method - meta-analysis.
The term “meta-epidemiology” ﬁrst appeared in literature in 1997 in David
Naylor’s editorial for meta-analysis in clinical research [1]. It was deﬁned
by Sterne and his colleagues in 2002 as a statistical method to identify
and quantify the inﬂuence of study level characteristics such as allocation
concealment in randomised controlled trials [2]. Since then, several papers
have been published with regard to “meta-epidemiology” [3,4]. The con-
cept, however, had not been generalised until 2007 when the Osteoarthritis
Research Society International (OARSI) had its ﬁrst systematic review of 51
treatments in osteoarthritis (OA) where research evidence including clinical
effectiveness and cost-effectiveness were analysed, compared and sum-
marised across treatments [5]. Meta-epidemiology is no longer a statistical
method, but instead translational research to close the gap between bench
work and bedside. The concept is further reinforced by the OARSI recent
update on research evidence in OA therapy [6]. A full picture of meta-
epidemiology starts fading into OA therapy with more epidemiological
aspects including distribution of evidence, change of evidence, associated
risk factors, bias of evidence, summary and clinical application of evidence.
Meta-epidemiology is not only a subject in the therapeutic area. It spreads
very quickly, for example into other OA areas, from genetic [7] to clinical
practice [8], from treatment effect [9] to contextual therapy [10], from
randomised control trials [11] to observational studies [12]. We anticipate
that in the next 5 years, this subject will further evolve to improve the
evidence based clinical practice.
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I-02
CARTILAGE INSIDE OUT
R. Poole
McGill Univ., Montreal, QC, Canada
Recent "inside" studies of the molecular pathology of cartilage degeneration
in osteoarthritis (OA) have provided a broad body of information. Much
of this can be explained by a unifying hypothesis involving chondrocyte
differentiation from what is normally seen in healthy uncalciﬁed articular
cartilage to a phenotype usually only found in endochondral ossiﬁca-
tion.This hypothesis and the mechanisms involved in regulation of this
chondrocyte hypertrophy will be reviewed.
New "outside" information involving the use of molecular biomarker anal-
yses of body ﬂuids to study joint pain will also be presented. This approach
shows promise in helping clarify our understanding of where joint pain
originates, especially in knee OA.
I-03
USINGMICROARRAYS TO INFORM LABORATORY AND CLINICAL PRACTICE
C.L. Murphy
Kennedy Inst. of Rheumatology, London, United Kingdom
Whether genome-wide, tissue, cell or pathway-speciﬁc, microarrays can be
a very useful tool in basic and translational science. With the development
of array technology, smaller and smaller amounts of RNA and therefore
tissue samples are required, and so the emphasis is on quality rather than
quantity of material used. However, meticulous experimental planning and
execution are crucial at every stage if meaningful data are to be obtained.
Firstly, careful consideration must be given as to whether arrays are the
right tool to answer the research question posed. For example, it must be
borne in mind that arrays yield gene expression data which are an average
of the sample being analysed. If that sample is complex, for example, a
tissue containing multiple cell types, then the results can be uninformative
if the goal is to understand a particular cell’s behaviour. In such cases, other
approaches may be more appropriate, for example, in situ hybridisation to
assess gene expression in a localised manner.
Another crucial aspect in array studies is the use of relevant controls
(positive or negative). Without such, no context can be provided for
interpretation of the data. This applies equally to all array-based studies.
One example is that of analysing gene expression of differentiating stem
cells. If experimentally induced differentiation to a particular cell type is
to be truly assessed, a comparison must be made with the terminally
differentiated cell in question. By way of illustration, if chondrogenic
differentiation of stem cells is being examined with regard to procuring
cells for articular cartilage repair therapies, then it is most important to
compare the stem-cell derived cells to mature articular chondrocytes. A
modest increase in chondrogenic markers in differentiating stem cells can
be shown to be less signiﬁcant if that gene expression remains orders of
magnitude less than that found in the mature chondrocyte.
If a disease such as osteoarthritis is being studied, controls, although hard
to obtain, remain essential. Comparing, for example, gene expression in
osteoarthritic cartilage to normal can be performed using tissue from the
